Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab for bullous pemphigoid
ACTRN12607000104459Phase 4Completed
- Sponsor
- Peter MacCallum Cancer Centre
- Start
- Jan 2005
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of rituximab in Bullous Pemphigoid (BP), sponsored by Peter MacCallum Cancer Centre. Primary endpoint: Patient response rate. Started Jan 2005; status: completed.
02
Drugs
rituximab
03
Conditions
Bullous Pemphigoid (BP)
Beyond the preview
Go deeper on ACTRN12607000104459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12607000104459.